Telos Capital Management Inc. Sells 68,245 Shares of Bristol-Myers Squibb (NYSE:BMY)

Telos Capital Management Inc. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 26.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 192,259 shares of the biopharmaceutical company’s stock after selling 68,245 shares during the period. Bristol-Myers Squibb comprises 1.2% of Telos Capital Management Inc.’s holdings, making the stock its 27th largest holding. Telos Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $9,865,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BMY. True Wealth Design LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $26,000. Coppell Advisory Solutions Corp. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $31,000. Coppell Advisory Solutions LLC purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth about $28,000. Live Oak Investment Partners purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $33,000. Finally, OFI Invest Asset Management purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $25,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 0.6 %

Shares of NYSE:BMY traded down $0.28 during trading hours on Wednesday, hitting $47.98. The company’s stock had a trading volume of 6,515,488 shares, compared to its average volume of 15,773,822. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The company has a market capitalization of $97.24 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 1.46 and a beta of 0.39. The firm’s fifty day moving average price is $51.27 and its 200 day moving average price is $51.62.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.82 EPS. As a group, research analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.00%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company lowered their price objective on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. Finally, Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.